You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

DLBCL, NOS

Showing 1 - 25 of 649
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Mature B-Cell Tumor, Non Hodgkin Lymphoma, DLBCL Trial (SGR-1505)

Not yet recruiting
  • Mature B-Cell Neoplasm
  • +25 more
  • (no location specified)
Sep 14, 2022

B-ALL, DLBCL, B ALL Trial in New York (131-I Apamistamab, CAR T-cell)

Recruiting
  • B-ALL
  • +10 more
  • 131-I Apamistamab
  • CAR T-cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 7, 2022

B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)

Recruiting
  • B-Cell Lymphoma
  • +4 more
  • 19(T2)28z1xx TRAC T cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Feb 24, 2023

Study of CAR-T Therapy in Older Patients

Recruiting
  • Lymphoma
  • +5 more
  • Activities of Daily Living/ADLs
  • +10 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jan 3, 2023

EBV-Positive DLBCL, Nos Trial in Guangzhou, Shanghai (Selinexor, R-CHOP Protocol)

Recruiting
  • EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
  • Guangzhou, Guangdong, China
  • +1 more
Nov 10, 2022

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (Toripalimab,

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • Toripalimab, Rituximab
  • R-CHOP Protocol
  • Guangzhou, Guangdong, China
    Department of hematology department, Nanfang hospital
Apr 6, 2022

Primary Mediastinal Large B Cell Lymphoma, EBV-Positive DLBCL, Nos Trial in Shanghai (Zanubrutinib, Tislelizumab)

Recruiting
  • Primary Mediastinal Large B Cell Lymphoma
  • EBV-Positive DLBCL, Nos
  • Shanghai, Shanghai, China
    Ruijin Hospital
Mar 29, 2021

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (Camrelizumab,

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Mar 10, 2021

Chemo, DLBCL (DLBCL), Nos, Elderly Trial in Amiens (Rituximab, Lenalidomide 20 MG, Comprehensive Geriatric Assessment (CGA))

Recruiting
  • Chemotherapy
  • +2 more
  • Amiens, France
    CHU Amiens
Jul 26, 2021

Non-GCB/ABC DLBCL, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (PD-1 Antibody, Lenalidomide)

Recruiting
  • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
  • +5 more
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Mar 12, 2021

Recurrent DLBCL, Refractory DLBCL Trial in Houston (Chemotherapy, Computed Tomography, Fludeoxyglucose F-18)

Completed
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Oct 27, 2022

EBV-Positive DLBCL, Nos Trial in China (Sintilimab, Rituximab, Cyclophosphamide)

Recruiting
  • EBV-Positive DLBCL, Nos
  • ChangZhou, Jiangsu, China
  • +10 more
Nov 27, 2019

Epstein-Barr Virus Associated Lymphoproliferative Disorder, EBV-Related PTLD, EBV Related Non-Hodgkin's Lymphoma Trial in

Recruiting
  • Epstein-Barr Virus Associated Lymphoproliferative Disorder
  • +7 more
  • Nanatinostat in combination with valganciclovir
  • Birmingham, Alabama
  • +57 more
Aug 10, 2022

Diffuse Large-cell B-cell Lymphoma Trial in Seattle (plamotamab, tafasitamab, lenalidomide)

Recruiting
  • Diffuse Large-cell B-cell Lymphoma
  • plamotamab
  • +2 more
  • Seattle, Washington
    Swedish Cancer Center
May 2, 2022

Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,

Suspended
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy Trial in United States (Emavusertib, ibrutinib)

Recruiting
  • Relapsed Hematologic Malignancy
  • Refractory Hematologic Malignancy
  • Phoenix, Arizona
  • +10 more
Feb 1, 2023

Multiple Myeloma (MM), DLBCL, Not Otherwise Specified, Double Hit Lymphoma Trial in Spain (IDP-121)

Recruiting
  • Multiple Myeloma (MM)
  • +5 more
  • Santander, Cantabria, Spain
  • +4 more
Jun 19, 2023

Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston

Active, not recruiting
  • Anaplastic Large Cell Lymphoma
  • +4 more
  • Duarte, California
  • +3 more
Jul 21, 2022

Non-Hodgkin Lymphoma Trial in Taiwan, United States (CHO-H01)

Recruiting
  • Non-Hodgkin Lymphoma
  • CHO-H01
  • The Woodlands, Texas
  • +7 more
Jul 10, 2023

Non-Hodgkin Lymphoma Trial in Switzerland (Copanlisib, Venetoclax)

Terminated
  • Non-Hodgkin Lymphoma
  • Basel, Switzerland
  • +5 more
Mar 18, 2022

B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia Trial in France, United States (XmAb13676)

Recruiting
  • B-cell Non-Hodgkins Lymphoma
  • Chronic Lymphocytic Leukemia
  • XmAb13676
  • La Jolla, California
  • +21 more
Oct 20, 2021

B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (IKS03)

Not yet recruiting
  • B-cell Non-Hodgkin Lymphoma
  • +4 more
  • (no location specified)
Dec 7, 2022

Diffuse Large B Cell Lymphoma Trial in Worldwide (Radiation Therapy)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Radiation Therapy
  • Boston, Massachusetts
  • +12 more
Jul 23, 2021

Alcohol Use Disorder Trial ([18F]NOS)

Not yet recruiting
  • Alcohol Use Disorder
  • (no location specified)
May 22, 2023